Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
6 evidence topics · 3 sources
Severe late toxicity after concurrent chemoradiotherapy
“Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube ≥ 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Swallowing, speech, and voice impairment in survivors
“Swallowing and speech impairments occur in ~50% of HNSCC survivors following radiotherapy treatment and are often present long-term” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, a majority (68%) of HNSCC survivors reported voice problems even 10 years after radiotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the two-year prevalence of dysphagia is 45% among HNSCC survivors (all therapies) and is 4–8 times more likely to occur in these individuals than in those who never had cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic dysphagia and aspiration after combined modality therapy
Lymphedema and other long-term effects of surgery and radiotherapy
Second primary tumors after HPV-negative disease
Suicide among survivors
“In addition to deaths directly caused by HNSCC, survivors of this cancer have the second highest rate of suicide (63.4 cases per 100,000 individuals) after those with pancreatic cancer (86.4 cases per 100,000 individuals), compared with survivors of other cancers (23.6 cases per 100,000 individuals).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote